Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells

Genes and Development

Volumn 30, Issue 11, 2016, Pages 1278-1288

  Agger, Karl ^a,b   Miyagi, Satoru ^a,b,c,d   Pedersen, Marianne Terndrup ^a,b   Kooistra, Susanne M ^a,b,e   Johansen, Jens Vilstrup ^a   Helin, Kristian ^a,b,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c University of Copenhagen   (Denmark)

^d CHIBA UNIVERSITY   (Japan)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Acute myeloid leukemia; Epigenetics; H3K9 methylation; Histone demethylase; Interleukin 3; JMJD2

Indexed keywords

CD123 ANTIGEN; HISTONE DEMETHYLASE; JMJD2 PROTEIN; JMJD2A PROTEIN; JMJD2B PROTEIN; JMJD2C PROTEIN; KDM4 PROTEIN; MEIS1 PROTEIN; MESSENGER RNA; PROTEIN; TRANSCRIPTION FACTOR HOXA9; UNCLASSIFIED DRUG; AFIMOXIFENE; PROTEIN BINDING; TAMOXIFEN;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ECTOPIC EXPRESSION; GENE EXPRESSION; HISTONE DEMETHYLATION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; METHYLATION; PATHOPHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; LEUKEMIA, MYELOID, ACUTE; METHYLATION; MICE; MICE, KNOCKOUT; PROTEIN BINDING; TAMOXIFEN;

EID: 84974534167     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.280495.116     Document Type: Article

References (45)

1. Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, Nakitandwe J, Holmfeldt L, Parker M, Easton J, et al. 2015. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet 47: 330–337.
2. Bavetsias V, Lanigan RM, Ruda GF, Atrash B, McLaughlin MG, Tumber A, Mok NY, Le Bihan YV, Dempster S, Boxall KJ, et al. 2016. 8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one derivatives as potent, cell permeable, KDM4 (JMJD2) and KDM5 (JARID1) histone lysine demethylase inhibitors. J Med Chem 59: 1388–1409.
3. Bernt KM, Armstrong SA. 2011. A role for DOT1L in MLL-rearranged leukemias. Epigenomics 3: 667–670.
4. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, et al. 2011. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20: 66–78.
5. Berry WL, Janknecht R. 2013. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res 73: 2936–2942.
6. Broughton SE, Dhagat U, Hercus TR, Nero TL, Grimbaldeston MA, Bonder CS, Lopez AF, Parker MW. 2012. The GM-CSF/ IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev 250: 277–302.
7. Cai SF, Chen CW, Armstrong SA. 2015. Drugging chromatin in cancer: recent advances and novel approaches. Mol Cell 60: 561–570.
8. Chen CW, Armstrong SA. 2015. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Exp Hematol 43: 673–684.
9. Cheung N, Fung TK, Zeisig BB, Holmes K, Rane JK, Mowen KA, Finn MG, Lenhard B, Chan LC, So CW. 2016. Targeting aberrant epigenetic networks mediated by PRMT1 and KDM4Cin acute myeloid leukemia. Cancer Cell 29: 32–48.
10. Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH, Helin K. 2006. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 442: 307–311.
11. de Boer J, Walf-Vorderwulbecke V, Williams O. 2013. In focus: MLL-rearranged leukemia. Leukemia 27: 1224–1228.
12. Fodor BD, Kubicek S, Yonezawa M, O’Sullivan RJ, Sengupta R, Perez-Burgos L, Opravil S, Mechtler K, Schotta G, Jenuwein T. 2006. Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes Dev 20: 1557–1562.
13. Hojfeldt JW, Agger K, Helin K. 2013. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov 12: 917–930.
14. Iwamori N, Zhao M, Meistrich ML, Matzuk MM. 2011. The testis-enriched histone demethylase, KDM4D, regulates methylation of histone H3 lysine 9 during spermatogenesis in the mouse but is dispensable for fertility. Biol Reprod 84: 1225–1234.
15. Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, et al. 2009. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5: 31–42.
16. Jin C, Yang L, Xie M, Lin C, Merkurjev D, Yang JC, Tanasa B, Oh S, Zhang J, Ohgi KA, et al. 2014. Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens. Proc Natl Acad Sci 111: 9235–9240.
17. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA, et al. 2000. The interleukin-3 receptor α chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14: 1777–1784.
18. Kawazu M, Saso K, Tong KI, McQuire T, Goto K, Son DO, Wakeham A, Miyagishi M, Mak TW, Okada H. 2011. Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development. PLoS One 6: e17830.
19. Kleine-Kohlbrecher D, Christensen J, Vandamme J, Abarrategui I, Bak M, Tommerup N, Shi X, Gozani O, Rappsilber J, Salcini AE, et al. 2010. A functional link between the histone demethylase PHF8 and the transcription factor ZNF711 in X-linked mental retardation. Mol Cell 38: 165–178.
20. Klose RJ, Yamane K, Bae Y, Zhang D, Erdjument-Bromage H, Tempst P, Wong J, Zhang Y. 2006. The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature 442: 312–316.
21. Kooistra SM, Helin K. 2012. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 13: 297–311.
22. Kouzarides T. 2007. Chromatin modifications and their function. Cell 128: 693–705.
23. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, et al. 2006. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442: 818–822.
24. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. 1998. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 17: 3714–3725.
25. Langmead B, Trapnell C, Pop M, Salzberg SL. 2009. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 10: R25.
26. Lerdrup M, Johansen JV, Agrawal-Singh S, Hansen K. 2016. An interactive environment for agile analysis and visualization of ChIP-sequencing data. Nat Struct Mol Biol 23: 349–357.
27. Liu K, Zhu M, Huang Y, Wei S, Xie J, Xiao Y. 2015. CD123 and its potential clinical application in leukemias. Life Sci 122: 59–64.
28. Luo W, Chang R, Zhong J, Pandey A, Semenza GL. 2012. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci 109: E3367–E3376.
29. Muntean AG, Hess JL. 2012. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol 7: 283–301.
30. Nishinakamura R, Nakayama N, Hirabayashi Y, Inoue T, Aud D, McNeil T, Azuma S, Yoshida S, Toyoda Y, Arai K, et al. 1995. Mice deficient for the IL-3/GM-CSF/IL-5βc receptor exhibit lung pathology and impaired immune response, while βIL3 receptor-deficient mice are normal. Immunity 2: 211–222.
31. Pedersen MT, Agger K, Laugesen A, Johansen JV, Cloos PA, Christensen J, Helin K. 2014. The demethylase JMJD2C localizes to H3K4me3-positive transcription start sites and is dispensable for embryonic development. Mol Cell Biol 34: 1031–1045.
32. Pedersen MT, Kooistra SM, Radzisheuskaya A, Laugesen A, Johansen JV, Hayward DG, Nilsson J, Agger K, Helin K. 2016. Continual removal of H3K9 promoter methylation by Jmjd2 demethylases is vital for ESC self-renewal and early development. EMBO J (in press).
33. Rao RC, Dou Y. 2015. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer 15: 334–346.
34. Sadras T, Perugini M, Kok CH, Iarossi DG, Heatley SL, Brumatti G, Samuel MS, To LB, Lewis ID, Lopez AF, et al. 2014. Interleukin-3-mediated regulation of β-catenin in myeloid transformation and acute myeloid leukemia. J Leukoc Biol 96: 83–91.
35. Shi L, Sun L, Li Q, Liang J, Yu W, Yi X, Yang X, Li Y, Han X, Zhang Y, et al. 2011. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci 108: 7541–7546.
36. Somervaille TC, Cleary ML. 2006. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10: 257–268.
37. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 102: 15545–15550.
38. Testa U, Riccioni R, Militi S, Coccia E, Stellacci E, Samoggia P, Latagliata R, Mariani G, Rossini A, Battistini A, et al. 2002. Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 100: 2980–2988.
39. Testa U, Pelosi E, Frankel A. 2014. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res 2: 4.
40. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA. 2010. The Wnt/β-catenin pathway is required for the development of leukemia stem cells in AML. Science 327: 1650–1653.
41. Wang L, Chang J, Varghese D, Dellinger M, Kumar S, Best AM, Ruiz J, Bruick R, Pena-Llopis S, Xu J, et al. 2013. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun 4: 2035.
42. Westaway SM, Preston AG, Barker MD, Brown F, Brown JA, Campbell M, Chung CW, Diallo H, Douault C, Drewes G, et al. 2016a. Cell penetrant inhibitors of the KDM4 and KDM5 families of histone lysine demethylases. 1. 3-amino-4-pyridine carboxylate derivatives. J Med Chem 25: 1357–1369.
43. Westaway SM, Preston AG, Barker MD, Brown F, Brown JA, Campbell M, Chung CW, Drewes G, Eagle R, Garton N, et al. 2016b. Cell penetrant inhibitors of the KDM4 and KDM5 families of histone lysine demethylases. 2. Pyrido [3,4-d]pyrimidin-4(3H)-one derivatives. J Med Chem 25: 1370–1387.
44. Whetstine JR, Nottke A, Lan F, Huarte M, Smolikov S, Chen Z, Spooner E, Li E, Zhang G, Colaiacovo M, et al. 2006. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 125: 467–481.
45. Ye T, Krebs AR, Choukrallah MA, Keime C, Plewniak F, Davidson I, Tora L. 2011. seq MINER: an integrated ChIP-seq data interpretation platform. Nucleic Acids Res 39: e35.